Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Neutral
Key Numbers
Market Cap
$1B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Editas Medicine
Editas Medicine is a small-cap biotech company listed on the NASDAQ, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. CRISPR-based gene editing company focused on inherited eye diseases. With a $1B market capitalization and no current profitability, Editas Medicine has delivered revenue headwinds with revenue moving 0% over the past year.
Expert Coverage
Unlock Full EDIT Analysis
Expert analysis and coverage for Editas Medicine
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-05-13
More in Biotech & Genomics
LLY
Eli Lilly and Company
92
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%CRSP
CRISPR Therapeutics
89
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%BEAM
Beam Therapeutics
89
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3B